Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry

被引:85
作者
Chan, Wan
Cui, Liang
Xu, Guowang
Cai, Zongwei [1 ]
机构
[1] Hong Kong Baptist Univ, Dept Chem, Kowloon, Hong Kong, Peoples R China
[2] Chinese Acad Sci, Dalian Inst Chem Phys, Natl Chromatog R&A Ctr, Dalian 116023, Peoples R China
关键词
D O I
10.1002/rcm.2513
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prolonged exposure to aristolochic acid (AA) was shown to pose rapid progressive renal fibrosis in Belgian women in a slimming regime in the early 1990s. AA was also demonstrated to be strong carcinogen in rats. The carcinogenicity of AA is generally believed to be related to the nitro-reduction of AA, in which the aristolactam-nitriumion ion with a delocalized positive charge is the ultimate carcinogen. In this study, the phase I and phase II metabolism of AA was investigated by using an in vitro system with rat liver S9 and an in vivo animal study with Sprague-Dawley rats. AA was found to have been undergone hydroxylation, lactam formation, and desnitro and desmethyl transformations. Three conjugated metabolites of AA, namely the N- and O-glucuronides of aristolactams, were detected directly in pre-concentrated urine sample, with no acid hydrolysis or enzymatic digestion. Structural elucidation of the metabolites was performed by using liquid chromatography/tandem mass spectrometry (LC/MS/MS). The results indicated that N-glucuronidation was the major phase II metabolic pathway for the aristolactams formed by AA after their nitro-reduction. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1755 / 1760
页数:6
相关论文
共 22 条
[1]  
AKASU M, 1974, TETRAHEDRON LETT, P3609
[2]   Aristolochic acid as a probable human cancer hazard in herbal remedies: a review [J].
Arlt, VM ;
Stiborova, M ;
Schmeiser, HH .
MUTAGENESIS, 2002, 17 (04) :265-277
[3]   P-32-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy [J].
Bieler, CA ;
Stiborova, M ;
Wiessler, M ;
Cosyns, JP ;
deStrihou, CV ;
Schmeiser, HH .
CARCINOGENESIS, 1997, 18 (05) :1063-1067
[4]  
Bourland JA, 1998, DRUG METAB DISPOS, V26, P203
[5]   Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3 [J].
Cai, ZW ;
Qian, TX ;
Wong, RNS ;
Jiang, ZH .
ANALYTICA CHIMICA ACTA, 2003, 492 (1-2) :283-293
[6]  
Debelle FD, 2002, J AM SOC NEPHROL, V13, P431, DOI 10.1681/ASN.V132431
[7]   N-glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes [J].
Kaivosaari, S ;
Salonen, JS ;
Taskinen, J .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (03) :295-300
[8]   STUDIES ON THE METABOLISM OF ARISTOLOCHIC ACID-I AND ACID-II [J].
KRUMBIEGEL, G ;
HALLENSLEBEN, J ;
MENNICKE, WH ;
RITTMANN, N ;
ROTH, HJ .
XENOBIOTICA, 1987, 17 (08) :981-991
[9]   TUMOR INHIBITORS .1. ARISTOLOCHIC ACID, ACTIVE PRINCIPLE OF ARISTOLOCHIA INDICA [J].
KUPCHAN, SM ;
DOSKOTCH, RW .
JOURNAL OF MEDICINAL & PHARMACEUTICAL CHEMISTRY, 1962, 5 (03) :657-&
[10]   TUMOR-INDUCTION IN MICE FOLLOWING EXPOSURE TO ARISTOLOCHIC ACID [J].
MENGS, U .
ARCHIVES OF TOXICOLOGY, 1988, 61 (06) :504-505